PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis

Cell Reports

Volumn 5, Issue 2, 2013, Pages 314-322

  Jun, Sohee ^a   Lee, Sunhye ^a   Kim, Han Cheon ^a   Ng, Christopher ^a   Schneider, AndreaM ^a   Ji, Hong ^a   Ying, Haoqiang ^a   Wang, Huamin ^a   DePinho, RonaldA ^a   Park, Jae Il ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PCNA ASSOCIATED FACTOR; PROTEIN LAMTOR3; RAF PROTEIN; RAS PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; LAMTOR3 PROTEIN, MOUSE; PAF PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE FUNCTION; GENE INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOGENESIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RAF KINASES; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84887024828     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.09.026     Document Type: Article

References (35)

1. Abraham S.C., Wu T.T., Hruban R.H., Lee J.H., Yeo C.J., Conlon K., Brennan M., Cameron J.L., Klimstra D.S. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am. J. Pathol. 2002, 160:953-962.
2. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
3. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2002, 2:897-909.
4. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
5. Campbell P.M., Groehler A.L., Lee K.M., Ouellette M.M., Khazak V., Der C.J. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007, 67:2098-2106.
6. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 2011, 10:351-364.
7. Collins M.A., Bednar F., Zhang Y., Brisset J.C., Galbán S., Galbán C.J., Rakshit S., Flannagan K.S., Adsay N.V., Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J.Clin. Invest. 2012, 122:639-653.
8. Emanuele M.J., Ciccia A., Elia A.E., Elledge S.J. Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proc. Natl. Acad. Sci. USA 2011, 108:9845-9850.
9. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
10. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
11. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., van Heek N.T., Rosty C., Walter K., Sato N., Parker A., Ashfaq R., et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 2003, 162:1151-1162.
12. Iovanna J., Mallmann M.C., Gonçalves A., Turrini O., Dagorn J.C. Current knowledge on pancreatic cancer. Front. Oncol. 2012, 2:6.
13. Jung H.Y., Jun S., Lee M., Kim H.C., Wang X., Ji H., McCrea P.D., Park J.I. PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol. Cell 2013, 10.1016/j.molcel.2013.08.028.
14. Jung H.Y., Wang X., Jun S., Park J.I. Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation. J.Biol. Chem. 2013, 288:7252-7262.
15. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
16. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., Kuick R., Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63:2649-2657.
17. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
18. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3:459-465.
19. Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M., Chang W., Meng Z., Cheung P., Ji H., et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009, 460:66-72.
20. Povlsen L.K., Beli P., Wagner S.A., Poulsen S.L., Sylvestersen K.B., Poulsen J.W., Nielsen M.L., Bekker-Jensen S., Mailand N., Choudhary C. Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat. Cell Biol. 2012, 14:1089-1098.
21. Rajalingam K., Schreck R., Rapp U.R., Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 2007, 1773:1177-1195.
22. Rasheed Z.A., Yang J., Wang Q., Kowalski J., Freed I., Murter C., Hong S.M., Koorstra J.B., Rajeshkumar N.V., He X., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J.Natl. Cancer Inst. 2010, 102:340-351.
23. Robinson M.J., Stippec S.A., Goldsmith E., White M.A., Cobb M.H. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 1998, 8:1141-1150.
24. Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
25. Schaeffer H.J., Catling A.D., Eblen S.T., Collier L.S., Krauss A., Weber M.J. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 1998, 281:1668-1671.
26. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
27. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CACancer J. Clin. 2012, 62:10-29.
28. Surade S., Blundell T.L. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 2012, 19:42-50.
29. Sweet R.W., Yokoyama S., Kamata T., Feramisco J.R., Rosenberg M., Gross M. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 1984, 311:273-275.
30. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39:347-351.
31. Wielenga V.J., Smits R., Korinek V., Smit L., Kielman M., Fodde R., Clevers H., Pals S.T. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 1999, 154:515-523.
32. Wunderlich W., Fialka I., Teis D., Alpi A., Pfeifer A., Parton R.G., Lottspeich F., Huber L.A. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. J.Cell Biol. 2001, 152:765-776.
33. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
34. Yu P., Huang B., Shen M., Lau C., Chan E., Michel J., Xiong Y., Payan D.G., Luo Y. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 2001, 20:484-489.
35. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signalintegration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.